355 related articles for article (PubMed ID: 20686466)
1. Inflammatory bowel disease, irritable bowel syndrome, or what?: A challenge to the functional-organic dichotomy.
Long MD; Drossman DA
Am J Gastroenterol; 2010 Aug; 105(8):1796-8. PubMed ID: 20686466
[TBL] [Abstract][Full Text] [Related]
2. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation?
Keohane J; O'Mahony C; O'Mahony L; O'Mahony S; Quigley EM; Shanahan F
Am J Gastroenterol; 2010 Aug; 105(8):1788, 1789-94; quiz 1795. PubMed ID: 20389294
[TBL] [Abstract][Full Text] [Related]
3. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D
Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
[TBL] [Abstract][Full Text] [Related]
4. [Calprotectin in feces a well-documented marker of gastrointestinal inflammation. Indicates disease intensity--normalization of values predict mucosal healing].
Lasson A
Lakartidningen; 2010 Oct 27-Nov 2; 107(43):2645-9. PubMed ID: 21137533
[No Abstract] [Full Text] [Related]
5. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors.
Simrén M; Axelsson J; Gillberg R; Abrahamsson H; Svedlund J; Björnsson ES
Am J Gastroenterol; 2002 Feb; 97(2):389-96. PubMed ID: 11866278
[TBL] [Abstract][Full Text] [Related]
6. Faecal calprotectin: a new marker for Crohn's disease?
Wassell J; Dolwani S; Metzner M; Losty H; Hawthorne A
Ann Clin Biochem; 2004 May; 41(Pt 3):230-2. PubMed ID: 15117438
[TBL] [Abstract][Full Text] [Related]
7. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
[TBL] [Abstract][Full Text] [Related]
8. Characterization of IBS-like symptoms in patients with ulcerative colitis in clinical remission.
Jonefjäll B; Strid H; Ohman L; Svedlund J; Bergstedt A; Simren M
Neurogastroenterol Motil; 2013 Sep; 25(9):756-e578. PubMed ID: 23731196
[TBL] [Abstract][Full Text] [Related]
9. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.
Silberer H; Küppers B; Mickisch O; Baniewicz W; Drescher M; Traber L; Kempf A; Schmidt-Gayk H
Clin Lab; 2005; 51(3-4):117-26. PubMed ID: 15819166
[TBL] [Abstract][Full Text] [Related]
10. Multigene analysis can discriminate between ulcerative colitis, Crohn's disease, and irritable bowel syndrome.
von Stein P; Lofberg R; Kuznetsov NV; Gielen AW; Persson JO; Sundberg R; Hellstrom K; Eriksson A; Befrits R; Ost A; von Stein OD
Gastroenterology; 2008 Jun; 134(7):1869-81; quiz 2153-4. PubMed ID: 18466904
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of four fecal assays in the diagnosis of colitis.
Schoepfer AM; Trummler M; Seeholzer P; Criblez DH; Seibold F
Dis Colon Rectum; 2007 Oct; 50(10):1697-706. PubMed ID: 17762964
[TBL] [Abstract][Full Text] [Related]
12. Psychological adjustment and autonomic disturbances in inflammatory bowel diseases and irritable bowel syndrome.
Pellissier S; Dantzer C; Canini F; Mathieu N; Bonaz B
Psychoneuroendocrinology; 2010 Jun; 35(5):653-62. PubMed ID: 19910123
[TBL] [Abstract][Full Text] [Related]
13. The functional-organic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome.
Grover M; Herfarth H; Drossman DA
Clin Gastroenterol Hepatol; 2009 Jan; 7(1):48-53. PubMed ID: 18848909
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
15. The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission.
Hoekman DR; Zeevenhooven J; D'Haens GR; Benninga MA
Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1086-1090. PubMed ID: 28639969
[TBL] [Abstract][Full Text] [Related]
16. Is irritable bowel syndrome a low-grade inflammatory bowel disease?
Bercik P; Verdu EF; Collins SM
Gastroenterol Clin North Am; 2005 Jun; 34(2):235-45, vi-vii. PubMed ID: 15862932
[TBL] [Abstract][Full Text] [Related]
17. Faecal markers of gastrointestinal inflammation.
Sherwood RA
J Clin Pathol; 2012 Nov; 65(11):981-5. PubMed ID: 22813730
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of calprotectin in irritable bowel syndrome and in inflammatory bowel disease.
Grad C; David L; Portincasa P; Dumitraşcu DL
Rom J Intern Med; 2012; 50(1):3-6. PubMed ID: 22788087
[TBL] [Abstract][Full Text] [Related]
19. Faecal calprotectin concentrations in gastrointestinal diseases.
Wang S; Wang Z; Shi H; Heng L; Juan W; Yuan B; Wu X; Wang F
J Int Med Res; 2013 Aug; 41(4):1357-61. PubMed ID: 23723365
[TBL] [Abstract][Full Text] [Related]
20. [Irritable bowel syndrome and inflammatory bowel disease: Is there a connection?].
Mearin F; Perelló A; Balboa A
Gastroenterol Hepatol; 2009 May; 32(5):364-72. PubMed ID: 19442413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
